WallStSmart

Freeport-McMoran Copper & Gold Inc (FCX)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 80% more annual revenue ($46.72B vs $25.92B). SNY leads profitability with a 16.7% profit margin vs 8.5%. FCX appears more attractively valued with a PEG of 3.30. FCX earns a higher WallStSmart Score of 52/100 (C-).

FCX

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 6.0Value: 6.0Quality: 7.0
Piotroski: 3/9Altman Z: 1.68

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FCXUndervalued (+8.0%)

Margin of Safety

+8.0%

Fair Value

$71.14

Current Price

$57.09

$14.05 discount

UndervaluedFair: $71.14Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FCX2 strengths · Avg: 8.5/10
Market CapQuality
$82.05B9/10

Large-cap with strong market position

EPS GrowthGrowth
47.7%8/10

Earnings expanding 47.7% YoY

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

FCX4 concerns · Avg: 3.3/10
P/E RatioValuation
37.6x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.684/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.302/10

Expensive relative to growth rate

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : FCX

The strongest argument for FCX centers on Market Cap, EPS Growth.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : FCX

The primary concerns for FCX are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

FCX profiles as a value stock while SNY is a mature play — different risk/reward profiles.

FCX carries more volatility with a beta of 1.44 — expect wider price swings.

SNY is growing revenue faster at 6.9% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

FCX scores higher overall (52/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Freeport-McMoran Copper & Gold Inc

BASIC MATERIALS · COPPER · USA

Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?